Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBT: 2023-2025

Historic EBT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$30.3 million.

  • Monte Rosa Therapeutics' EBT fell 27.20% to -$30.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 118.45%. This contributed to the annual value of -$70.1 million for FY2024, which is 48.06% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' EBT stood at -$30.3 million, which was down 172.69% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EBT registered a high of $47.7 million during Q1 2025, and its lowest value of -$35.0 million during Q2 2023.
  • Its 3-year average for EBT is -$18.1 million, with a median of -$30.3 million in 2025.
  • The largest annual percentage gain for Monte Rosa Therapeutics' EBT in the last 5 years was 249.62% (2025), contrasted with its biggest fall of 27.20% (2025).
  • Monte Rosa Therapeutics' EBT (Quarterly) stood at -$33.3 million in 2023, then soared by 146.89% to $15.6 million in 2024, then fell by 27.20% to -$30.3 million in 2025.
  • Its EBT was -$30.3 million in Q3 2025, compared to -$11.1 million in Q2 2025 and $47.7 million in Q1 2025.